Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Melanie Joy to Humans

This is a "connection" page, showing publications Melanie Joy has written about Humans.

 
Connection Strength
 
 
 
0.631
 
  1. Tuey SM, Atilano-Roque A, Charkoftaki G, Thurman JM, Nolin TD, Joy MS. Influence of vitamin D treatment on functional expression of drug disposition pathways in human kidney proximal tubule cells during simulated uremia. Xenobiotica. 2021 Jun; 51(6):657-667.
    View in: PubMed
    Score: 0.026
  2. Fogueri U, Cheungapasitporn W, Bourne D, Fervenza FC, Joy MS. Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy. Ann Pharmacother. 2019 04; 53(4):357-363.
    View in: PubMed
    Score: 0.022
  3. Ibrahim ME, Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant CL, Bowles DW, George B, Wen X, Buckley B, Aleksunes L, Joy MS. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. Eur J Clin Pharmacol. 2019 Jan; 75(1):51-57.
    View in: PubMed
    Score: 0.021
  4. Shi Q, Jolly M, Mccord MG, Joy MS. Surface-Engineered Blood Adsorption Device for Hyperphosphatemia Treatment. ASAIO J. 2018 May/Jun; 64(3):389-394.
    View in: PubMed
    Score: 0.021
  5. Atilano-Roque A, Joy MS. Characterization of simvastatin acid uptake by organic anion transporting polypeptide 3A1 (OATP3A1) and influence of drug-drug interaction. Toxicol In Vitro. 2017 Dec; 45(Pt 1):158-165.
    View in: PubMed
    Score: 0.020
  6. Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant C, Bowles DW, George B, Wen X, Aleksunes LM, Joy MS. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. Int J Mol Sci. 2017 Jun 22; 18(7).
    View in: PubMed
    Score: 0.020
  7. Atilano-Roque A, Aleksunes LM, Joy MS. Bardoxolone methyl modulates efflux transporter and detoxifying enzyme expression in cisplatin-induced kidney cell injury. Toxicol Lett. 2016 Sep 30; 259:52-59.
    View in: PubMed
    Score: 0.019
  8. Atilano-Roque A, Roda G, Fogueri U, Kiser JJ, Joy MS. Effect of Disease Pathologies on Transporter Expression and Function. J Clin Pharmacol. 2016 07; 56 Suppl 7:S205-21.
    View in: PubMed
    Score: 0.018
  9. Awdishu L, Joy MS. Role of Pharmacogenomics in Kidney Disease and Injury. Adv Chronic Kidney Dis. 2016 Mar; 23(2):106-19.
    View in: PubMed
    Score: 0.018
  10. Ternant D, Paintaud G, Trachtman H, Gipson DS, Joy MS. A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). Eur J Clin Pharmacol. 2016 Feb; 72(2):253-5.
    View in: PubMed
    Score: 0.018
  11. Joy MS, Roberts BV, Wang J, Hu Y, Hogan SL, Falk RJ. A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis. Int J Clin Pharmacol Ther. 2014 Apr; 52(4):303-13.
    View in: PubMed
    Score: 0.016
  12. Joy MS, Frye RF, Nolin TD, Roberts BV, La MK, Wang J, Brouwer KL, Dooley MA, Falk RJ. In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy. 2014 Feb; 34(2):114-22.
    View in: PubMed
    Score: 0.015
  13. Roberts BV, Susano I, Gipson DS, Trachtman H, Joy MS. Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease. J Clin Pharmacol. 2013 Sep; 53(9):919-24.
    View in: PubMed
    Score: 0.015
  14. Jang SY, Dooley MA, Joy MS. Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis. Ann Pharmacother. 2013 Jul-Aug; 47(7-8):e35.
    View in: PubMed
    Score: 0.015
  15. Joy MS, La M, Wang J, Bridges AS, Hu Y, Hogan SL, Frye RF, Blaisdell J, Goldstein JA, Dooley MA, Brouwer KL, Falk RJ. Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol. 2012 Sep; 74(3):445-55.
    View in: PubMed
    Score: 0.014
  16. Joy MS. Impact of glomerular kidney diseases on the clearance of drugs. J Clin Pharmacol. 2012 Jan; 52(1 Suppl):23S-34S.
    View in: PubMed
    Score: 0.013
  17. Sam WJ, Joy MS. Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. Ther Drug Monit. 2010 Oct; 32(5):594-605.
    View in: PubMed
    Score: 0.012
  18. Joy MS, Boyette T, Hu Y, Wang J, La M, Hogan SL, Stewart PW, Falk RJ, Dooley MA, Smith PC. Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. Eur J Clin Pharmacol. 2010 Nov; 66(11):1119-30.
    View in: PubMed
    Score: 0.012
  19. Joy MS, Frye RF, Stubbert K, Brouwer KR, Falk RJ, Kharasch ED. Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol. 2010 Jun; 50(6):714-20.
    View in: PubMed
    Score: 0.012
  20. Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010 Jan; 55(1):50-60.
    View in: PubMed
    Score: 0.012
  21. Joy MS, Dornbrook-Lavender K, Blaisdell J, Hilliard T, Boyette T, Hu Y, Hogan SL, Candiani C, Falk RJ, Goldstein JA. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur J Clin Pharmacol. 2009 Sep; 65(9):947-53.
    View in: PubMed
    Score: 0.011
  22. Joy MS, Hilliard T, Hu Y, Hogan SL, Wang J, Falk RJ, Smith PC. Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Pharmacother. 2009 Jun; 43(6):1020-7.
    View in: PubMed
    Score: 0.011
  23. Hansen RA, Chin H, Blalock S, Joy MS. Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia care. Res Social Adm Pharm. 2009 Jun; 5(2):143-53.
    View in: PubMed
    Score: 0.011
  24. Joy MS, Hilliard T, Hu Y, Hogan SL, Dooley MA, Falk RJ, Smith PC. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy. 2009 Jan; 29(1):7-16.
    View in: PubMed
    Score: 0.011
  25. Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol. 2009 Jan; 4(1):39-47.
    View in: PubMed
    Score: 0.011
  26. Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca C. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Ann Pharmacother. 2008 Jan; 42(1):9-15.
    View in: PubMed
    Score: 0.010
  27. Joy MS, Matzke GR. Nephrology pharmacy: historical reflections and future challenges. Ann Pharmacother. 2007 Nov; 41(11):1884-6.
    View in: PubMed
    Score: 0.010
  28. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007 Jun; 13(5):397-411.
    View in: PubMed
    Score: 0.010
  29. Joy MS, Candiani C, Vaillancourt BA, Chin H, Hogan SL, Falk RJ. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease. Pharmacotherapy. 2007 May; 27(5):734-44.
    View in: PubMed
    Score: 0.010
  30. Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant. 2007 Jul; 22(7):1963-8.
    View in: PubMed
    Score: 0.010
  31. Joy MS, Kshirsagar A, Candiani C, Brooks T, Hudson JQ. Lanthanum carbonate. Ann Pharmacother. 2006 Feb; 40(2):234-40.
    View in: PubMed
    Score: 0.009
  32. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant. 2005 Dec; 20(12):2725-32.
    View in: PubMed
    Score: 0.009
  33. Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy. 2005 Jun; 25(6):779-89.
    View in: PubMed
    Score: 0.009
  34. Joy MS, DeHart RM, Gilmartin C, Hachey DM, Hudson JQ, Pruchnicki M, Dumo P, Grabe DW, Saseen J, Zillich AJ. Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy. Am J Kidney Dis. 2005 Jun; 45(6):1105-18.
    View in: PubMed
    Score: 0.009
  35. Joy MS, Kshirsagar AV, Franceschini N. Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Ann Pharmacother. 2004 Nov; 38(11):1871-80.
    View in: PubMed
    Score: 0.008
  36. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003 Jul; 42(1):96-107.
    View in: PubMed
    Score: 0.007
  37. Joy MS. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Ann Pharmacother. 2002 Jul-Aug; 36(7-8):1183-92.
    View in: PubMed
    Score: 0.007
  38. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2002 Feb; 39(2):297-307.
    View in: PubMed
    Score: 0.007
  39. George B, Wen X, Jaimes EA, Joy MS, Aleksunes LM. In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs. Int J Mol Sci. 2021 Jun 16; 22(12).
    View in: PubMed
    Score: 0.006
  40. Awdishu L, Le A, Amato J, Jani V, Bal S, Mills RH, Carrillo-Terrazas M, Gonzalez DJ, Tolwani A, Acharya A, Cerda J, Joy MS, Nicoletti P, Macedo E, Vaingankar S, Mehta R, RamachandraRao SP. Urinary Exosomes Identify Inflammatory Pathways in Vancomycin Associated Acute Kidney Injury. Int J Mol Sci. 2021 Mar 10; 22(6).
    View in: PubMed
    Score: 0.006
  41. Joy MS, Neyhart CD, Dooley MA. A multidisciplinary renal clinic for corticosteroid-induced bone disease. Pharmacotherapy. 2000 Feb; 20(2):206-16.
    View in: PubMed
    Score: 0.006
  42. Joy MS, Matzke GR, Frye RF, Palevsky PM. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis. 1998 Jun; 31(6):1019-27.
    View in: PubMed
    Score: 0.005
  43. Nachman PH, Joy MS. Glycosylated hemoglobin in the care of patients with diabetes mellitus. ANNA J. 1998 Apr; 25(2):245-6.
    View in: PubMed
    Score: 0.005
  44. Gist KM, Cooper DS, Wrona J, Faubel S, Altmann C, Gao Z, Marino BS, Alten J, Hock KM, Mizuno T, Vinks AA, Joy MS, Wempe MF, Bennett MR, Goldstein SL. Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Serum Creatinine-Defined Acute Kidney Injury in Infants After Cardiac Surgery. Ther Drug Monit. 2018 04; 40(2):186-194.
    View in: PubMed
    Score: 0.005
  45. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998 Mar; 32(3):362-75.
    View in: PubMed
    Score: 0.005
  46. George B, Joy MS, Aleksunes LM. Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Exp Biol Med (Maywood). 2018 02; 243(3):272-282.
    View in: PubMed
    Score: 0.005
  47. Joy MS. Clonazepam: benzodiazepine therapy for the restless legs syndrome. ANNA J. 1997 Dec; 24(6):686-9.
    View in: PubMed
    Score: 0.005
  48. Wen X, Joy MS, Aleksunes LM. In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants. Pharm Res. 2017 Aug; 34(8):1637-1647.
    View in: PubMed
    Score: 0.005
  49. George B, Wen X, Mercke N, Gomez M, O'Bryant C, Bowles DW, Hu Y, Hogan SL, Joy MS, Aleksunes LM. Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity. Clin Pharmacol Ther. 2017 04; 101(4):510-518.
    View in: PubMed
    Score: 0.005
  50. George B, You D, Joy MS, Aleksunes LM. Xenobiotic transporters and kidney injury. Adv Drug Deliv Rev. 2017 07 01; 116:73-91.
    View in: PubMed
    Score: 0.005
  51. Gist KM, Goldstein SL, Joy MS, Vinks AA. Milrinone Dosing Issues in Critically Ill Children With Kidney Injury: A Review. J Cardiovasc Pharmacol. 2016 Feb; 67(2):175-81.
    View in: PubMed
    Score: 0.004
  52. Thurman JM, Wong M, Renner B, Frazer-Abel A, Giclas PC, Joy MS, Jalal D, Radeva MK, Gassman J, Gipson DS, Kaskel F, Friedman A, Trachtman H. Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS One. 2015; 10(9):e0136558.
    View in: PubMed
    Score: 0.004
  53. Cleary DJ, Matzke GR, Alexander AC, Joy MS. Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm. 1995 Sep 01; 52(17):1895-900.
    View in: PubMed
    Score: 0.004
  54. Wen X, Thorne G, Hu L, Joy MS, Aleksunes LM. Activation of NRF2 Signaling in HEK293 Cells by a First-in-Class Direct KEAP1-NRF2 Inhibitor. J Biochem Mol Toxicol. 2015 Jun; 29(6):261-6.
    View in: PubMed
    Score: 0.004
  55. Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, Smith PC, Joy MS, Guillemette C. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab Dispos. 2015 Apr; 43(4):611-9.
    View in: PubMed
    Score: 0.004
  56. Ménard V, Lévesque E, Chen S, Eap O, Joy MS, Ekström L, Rane A, Guillemette C. Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer. Pharmacogenet Genomics. 2013 Dec; 23(12):684-96.
    View in: PubMed
    Score: 0.004
  57. Fink JC, Joy MS, St Peter WL, Wahba IM. Finding a common language for patient safety in CKD. Clin J Am Soc Nephrol. 2012 Apr; 7(4):689-95.
    View in: PubMed
    Score: 0.003
  58. Nyman HA, Dowling TC, Hudson JQ, Peter WL, Joy MS, Nolin TD. Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy. 2011 Nov; 31(11):1130-44.
    View in: PubMed
    Score: 0.003
  59. Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, Savin V, Somers M, Pinsk M, Greene T. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol. 2011 Feb 10; 12:8.
    View in: PubMed
    Score: 0.003
  60. Stanton ML, Joy MS, Frye RF. Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Feb 01; 878(3-4):497-501.
    View in: PubMed
    Score: 0.003
  61. Lionaki S, Hogan SL, Falk RJ, Joy MS, Jennette CE, Nachman PH, Jennette JC. Vasculitis and anti-thyroid medication. Nephrol Dial Transplant. 2008 May; 23(5):1766-8; author reply 1768.
    View in: PubMed
    Score: 0.003
  62. Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Jennette JC, Nachman PH. Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant. 2007 Dec; 22(12):3508-15.
    View in: PubMed
    Score: 0.002
  63. Finn WF, Joy MS. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin. 2005 May; 21(5):657-64.
    View in: PubMed
    Score: 0.002
  64. Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy. 2005 Mar; 25(3):335-44.
    View in: PubMed
    Score: 0.002
  65. Zillich AJ, Saseen JJ, Dehart RM, Dumo P, Grabe DW, Gilmartin C, Hachey DM, Hudson JQ, Pruchnicki MC, Joy MS. Caring for patients with chronic kidney disease: a joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical Pharmacy. Pharmacotherapy. 2005 Jan; 25(1):123-43.
    View in: PubMed
    Score: 0.002
  66. Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004 Sep; 62(3):193-201.
    View in: PubMed
    Score: 0.002
  67. Franceschini N, Joy MS, Kshirsagar A. Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism. Expert Opin Investig Drugs. 2003 Aug; 12(8):1413-21.
    View in: PubMed
    Score: 0.002
  68. ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother. 2002 Jan; 36(1):130-47.
    View in: PubMed
    Score: 0.002
  69. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother. 2000 Jun; 44(6):1639-44.
    View in: PubMed
    Score: 0.002
  70. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy. 2000 Jun; 20(6):635-43.
    View in: PubMed
    Score: 0.002
  71. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis. 2000 Apr; 35(4):695-707.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)